Hims & Hers Health, Inc. Class A Common Stock (HIMS)

What happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 18.5% in the afternoon session after the company reported its financial resul...

Management is betting that a lighter marketing push now sets Hims & Hers up for the January weight-loss surge, but it's unclear whether lost subscribers will return.

International expansion offset a U.S. subscriber slowdown in the quarter.

Telehealth company Hims & Hers Health (NYSE:HIMS) met Wall Street’s revenue expectations in Q3 2026, with sales up 48.6% year on year to $890.4 million. On t...

Hims & Hers Health (NYSE:HIMS) reported third-quarter revenue growth of 49% but lost 100,000 subscribers from the prior quarter, as the digital health company held back U.S. weight-loss marketing and consolidated brands in international markets. Revenue rose to $890 million, while subscribers i

Telehealth company Hims & Hers Health (NYSE:HIMS) met Wall Street’s revenue expectations in Q3 2026, with revenue up 48.6% year on year to $890.4 million. On...

Telehealth company Hims & Hers Health (NYSE:HIMS) will be reporting earnings this Monday after market close. Here’s what you need to know. Hims & Hers Health...

Both are disruptors, but one of these growth stocks stands out over the other.

What happened? A number of stocks jumped in the afternoon session after election results confirmed that Democrats reclaimed majorities in the House and Senat...

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv...

Several catalysts could sustain robust growth for Hims.

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline...

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va...

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on...

The market landscape is increasingly controlled by large firms that expand their reach by acquiring smaller competitors - a trend that the Trump administrati...

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Cas...

The past six months have been a windfall for Hims & Hers Health’s shareholders. The company’s stock price has jumped 40.2%, hitting $29.23 per share. This wa...

Hims & Hers Health shares fell 6.7% amid an FTC lawsuit over privacy and billing practices, a new securities class action, and a Q2 earnings miss that has weighed on the stock in 2026.

HIMS, ONDS, COIN, and SOFI show elevated short interest, but days-to-cover ratios, institutional ownership, and upcoming earnings reports suggest differing outlooks for short sellers.

The insider still retains significant holdings, valued at $8.5 million, despite the sale.

Hims & Hers surpassed the three million member milestone.

Hims & Hers Health is still growing rapidly, but whether that growth can translate into better economics could determine how much further the stock can climb.

MarketBeat analysts recap a mixed earnings week, covering AI infrastructure demand, retail's K-shaped consumer trends, Meta's $18 billion settlement, and stock picks across tech, biotech, and retail sectors.